Robson, M., Yap, T. A., Gupta, G. P., Andres, R., Carrascal, E. M. C., Harrop, B., Headley, D., Millward, H., Skelton, S., Baxter, C. L., Little, N., Dickinson, P. A., Stuart, M., Smith, G., Smith, I. C. (2026). Phase IIa, open-label, multi-center study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1165